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It is now well established that proteolytic enzymes produced by
cancer cells and/or cells in tumour stroma are involved in the
intensive tissue remodelling, which accompanies cancer cell inva-
sion and metastasis (Danø et al, 1994; Andreasen et al, 1997).
Among the several enzyme systems expressed in cancer tissue,
urokinase-catalysed plasminogen activation is thought to play a
key role in tissue degradation (Danø et al, 1985; Shapiro et al,
1996), activation of pro-metalloproteinases (He et al, 1989;
Baramova et al, 1997) and activation of cytokines (Lyons et al,
1990), all of which could lead to increased metastatic potential of
the cancer cells. The urokinase plasminogen activator (uPA) has a
specific cell surface receptor (uPAR) that is a 55–60kDa, highly
glycosylated protein, consisting of three homologous domains, the
amino-terminal domain 1 as well as the other two domains being
important for high affinity binding of the growth factor domain of
uPA (Ploug et al, 1998). The carboxy-terminal of uPAR is attached
to the cell surface by a glycosylphosphatidylinositol (GPI)-anchor,
so that binding of the inactive proenzyme of uPA to uPAR and
concomitant cell surface binding of plasminogen strongly
enhances plasmin generation (Ellis et al, 1991). Binding of uPA
to uPAR also promotes binding of uPAR to the adhesive matrix
protein vitronectin, a process which is reversed by the plas-
minogen activator inhibitor type-1 (PAI-1), a competitor of uPAR
binding to vitronectin (Deng et al, 1996).
In vitro studies have suggested that full-length three-domain
uPAR protein can be released from the surface of human cells (Lau
and Kim, 1994), but the mechanism of this is unclear. Bacterial
phospholipase C can cleave the glycolipid anchor (Ploug et al,
1991), while no mammalian phospholipase of appropriate speci-
ficity is known. Proteolytic cleavage between domains 1 and 2 can
release soluble domain 1, but no free domain 1 has been demon-
strated in cell culture supernatants so far. If cleavage by phospho-
lipases and/or proteases occurred in vivo, soluble uPAR (suPAR)
consisting of the full-length three-domain protein, or the domains
(2+3 and 1) form of the receptor, all without glycolipid anchor,
could be expected in peripheral blood. Recently we have reported
that shuPAR is found in sera and plasma from healthy blood
donors at a median concentration of approximately 1.2ng ml–1
(Stephens et al, 1997), but the mechanism of release remains
unclear. uPAR is known to be displayed on the surface of human
blood monocytes and neutrophils (Plesner et al, 1997), so that
senescence of these cells could be one source of suPAR in blood.
The differentiation of megakaryocytes and formation of platelets
in bone marrow may also contribute significant levels of suPAR to
the blood compartment (Wohn et al, 1997).
In recent studies of patients with non-small cell lung cancer
(Pappot et al, 1997), breast and colon cancer (Stephens et al, 1997)
and ovarian cancer (Sier et al, 1998), the concentration of shuPAR
was found to be significantly increased in patient plasma as
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SummaryThe urokinase plasminogen activator receptor (uPAR) plays a critical role in urokinase-mediated plasminogen activation and
thereby in the process leading to invasion and metastasis. Soluble urokinase receptor (suPAR) is released from tumours, and in cancer
patients the blood level of soluble receptor is increased. Using an enzyme-linked, immunosorbent assay (ELISA)-specific for the human
urokinase receptor, release of soluble receptor was measured in cultures of human breast carcinoma cells, in tumour extracts and in plasma
from mice with xenografted human tumours. Soluble human urokinase receptor (shuPAR) was released into culture supernatant during the
growth of the human breast cancer cell line MDA-MB-231 BAG, and the level of shuPAR in conditioned medium determined by ELISA was a
linear function of both viable cell number and time of incubation. Western blotting showed that the form of shuPAR measured by ELISA in
conditioned medium consisted virtually exclusively of the three-domain full-length protein, while uPAR in cell lysates consisted of full-length
uPAR as well as the domains (2+3) cleavage product. shuPAR was also released into the plasma of nude mice during growth of MDA-MB-231
BAG, MDA-MB-435 BAG and HCT 116 cells as subcutaneously xenografted tumours. Western blotting demonstrated that the shuPAR
released from the xenografted human tumours into plasma consisted of the three-domain full-length protein, despite the finding of some
cleaved uPAR in detergent extracts of tumour tissue. The levels of shuPAR determined by ELISA in the plasma of host mice during the growth
of xenografted cell lines were highly correlated with tumour volume.
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©1999 Cancer Research Campaigncompared to healthy individuals. We proposed that the increase in
blood shuPAR in cancer patients was due to release from the
surface of tumour and/or stromal cells in the cancer tissue (Pappot
et al, 1997; Stephens et al, 1997). In patients with ovarian cancer,
at least part of the suPAR present in the ascites fluid consists of all
three protein domains, and thus retains its ability to bind uPA
(Pedersen et al, 1993). However, no direct demonstration has been
reported of the relationship between plasma suPAR levels and
tumour burden, nor has the possible biological role of suPAR been
clarified.
Previous studies have shown that uPAR as measured in extracts
of tumour tissue provides significant prognostic information. High
levels of uPAR in extracts of tumour tissue is associated with short
survival in patients with lung, colon and breast cancers (Ganesh
et al, 1994; Pedersen et al, 1994; Grøndahl-Hansen et al, 1995).
These prognostic studies have now been extended to measure-
ments of shuPAR in peripheral blood, and we have recently shown
that high levels of shuPAR in plasma are associated with shorter
survival in patients with colorectal cancer (Stephens et al, 1999)
and ovarian cancer (Sier et al, 1998). While elevated levels of
shuPAR were found even in early-stage disease (e.g. Dukes’ B
colon cancer), higher levels of shuPAR were associated with
advanced disease, suggesting that plasma shuPAR levels may bear
a complex relation to both tumour invasive activity as well
as tumour burden.
Using a newly developed sensitive and specific enzyme-linked
immunosorbent assay (ELISA) for human uPAR (Stephens et al,
1997), together with immunoabsorption and Western blotting, we
have now measured and characterized the shuPAR released in
vitro from human carcinoma cells. Moreover, we have quantitated
and characterized shuPAR found in the host plasma of nude mice
carrying human cancer xenografts. The experimental data demon-
strate that plasma levels of shuPAR reflect tumour burden in
animal models.
MATERIALS AND METHODS
Antibodies and uPAR standards
A mouse monoclonal antibody (mAb) designated clone R2, with
high affinity and specificity for domain 3 of human uPAR was
used as capture antibody for the shuPAR ELISA (Rønne et al,
1995), and purified rabbit polyclonal anti-human uPAR antibodies
(Stephens et al, 1997) were used for detection in both ELISA
and Western blotting. The mouse mAbs against human uPAR
designated clones R2 and R4 (Rønne et al, 1995) were used for
immunoabsorption, which also employed a control mouse mAb
against the 2,4,6-trinitrophenyl hapten (TNP) (Rønne et al, 1995).
Purified recombinant shuPAR (Rønne et al, 1994) was used as
standard in the ELISA. Full-length shuPAR and chymotrypsin-
cleaved shuPAR for use as standards in the Western blotting were
prepared as described (Ploug et al, 1994). Purified recombinant
soluble mouse uPAR (smuPAR) from a Chinese hamster ovary cell
expression system was a kind gift from Dr Helene Solberg.
Cell lines
The MDA-MB-231 human breast cancer cell line was originally
obtained from ATCC (Maryland, USA) and the MDA-MB 435
human breast cancer cell line was kindly provided by Dr Janet
Price (MD Anderson Hospital, Houston, TX, USA). The breast
cancer cell lines were transduced with the BAG vector as
described (Brünner et al, 1992). We have previously characterized
these two cell lines with regard to protein expression of the
uPA system in vitro (Holst-Hansen et al, 1996). The cells were
routinely propagated in Eagle’s modified essential medium
(MEM) with Glutamax-1 (Life Technologies) and supplemented
with 5% fetal calf serum (FCS). The HCT 116 human colon cancer
cell line was kindly provided by Dr A Dragone (Boehringer
Mannheim, Monza, Italy). The cells were routinely propagated in
McCoy’s 5A with Glutamax-1 (Life Technologies), 20 mM
HEPES and 10% FCS. All cell lines were tested by immunofluo-
rescence, polymerase chain reaction (PCR) and DNA staining and
found to be free from mycoplasma contamination.
Conditioned media
Cells were harvested with trypsin–EDTA and added in complete
FCS supplemented medium to 24-well cluster plates at a cell
density of 25 000 cells per well or as indicated. Next day the
adherent monolayers were washed twice in phosphate-buffered
saline (PBS) and the medium was changed to serum-free condi-
tions using 0.1% bovine serum albumin (BSA; Fraction V, Sigma)
and 10 mM HEPES in Eagles MEM supplemented with Glutamax-
1 (SFM). Cells were incubated at 37°C for 24 or 48 h as indicated.
Conditioned media were collected and centrifuged at 10 000 g for
5 min at 4°C. Some conditioned media were ultracentrifuged at
105 000 g for 60 min at 4°C. Supernatants were frozen and stored
at –80°C until analysed. Viable cells were quantitated by the
3-(4,5-dimethylthiazal-2-y1)-2,5-diphenyltetrazolium bromide
(MTT)-method (Sigma Chemicals) as described previously
(Holst-Hansen et al, 1996).
Cell lysates
For cell lysates, MDA-MB-231 BAG cells were cultured under
serum-free conditions for 48 h and then harvested by scraping with
a rubber policeman. Cells were lysed by addition of 1 ml of lysis
buffer (0.1 M Tris–HCl, pH 8.1, 1% Triton X-114, 10 mM EDTA,
10 mgm l –1 aprotinin, 1 mM phenylmethylsulphonyl fluoride
(PMSF)) to 5 ´ 107 cells. The lysates were subjected to tempera-
ture-induced phase separation (Behrendt et al, 1990), and the
resulting supernatants were subsequently analysed by Western
blotting (see below).
shuPAR ELISA
shuPAR was determined in undiluted culture supernatants and in
1:10 dilutions of mouse plasma made in a sample dilution buffer of
50 M phosphate, pH 7.2, 0.1 M sodium chloride, 10 mg ml–1 BSA
(Fraction V, Boehringer Mannheim), 1 mg ml–1 Tween-20, using a
new kinetic ELISA which meets strict criteria of specificity and
sensitivity (Stephens et al, 1997). To avoid a high background
signal from mouse plasma, the catching and detection layers were
inverted, so that the catching layer consisted of the monoclonal
antibody R2 (coated at 2 mg ml–1), which is directed against
domain 3 of the human uPAR molecule. Thus both the full-length
(domains 1+2+3) and proteolytically cleaved (domains (2+3))
forms of shuPAR were measured by this assay. The detection layer
consisted of rabbit polyclonal antibodies to human uPAR (used at
1 mg ml–1), as previously used for capturing shuPAR in ELISA
(Stephens et al, 1997). A monoclonal anti-rabbit immunoglobulin–
alkaline phosphatase conjugate (Sigma Chemicals, St Louis, MO,
USA; dilution 1:2000) was used in the final step, so that rate
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tion period in a Ceres 900TM plate reader (Bio-Tek Instruments,
Winooski, VT, USA). The limit of detection for the assay was
0.003 ng ml–1. The intra-assay variation for a pool of human citrate
plasma was 4.8% (n = 21), and the inter-assay variation for
30 successive assays of aliquots of the same plasma pool (on
different days) was 7.6%. shuPAR was evidently stable in frozen
plasma for at least several months.
Recovery of standard shuPAR and smuPAR signal in
mouse plasma
The recovery of signal from standard shuPAR was tested after
addition to a 1:10 dilution of mouse citrate plasma pool. Standard
shuPAR was added to the diluted plasma to give final concentra-
tions in the range 0–1.0 ng shuPAR ml–1. The recoveries in each
case were calculated from the slopes of the lines representing
shuPAR signal as a function of concentration, where 100%
recovery was defined as the slope obtained when shuPAR was
diluted in the sample dilution buffer (see ELISA above).
The recovery of signal from standard smuPAR was also tested
after addition to a 1:10 dilution of mouse citrate plasma pool.
Standard smuPAR was added to the diluted plasma to give final
concentrations in the range 0–10 ng smuPAR ml–1. One hundred
per cent recovery was defined as the slope obtained when smuPAR
was diluted in the sample dilution buffer.
Animal experiments
Six- to 8-week-old intact female nu/nu-META/Bom (Bomholt-
gaard, Ry, Denmark) mice were used in all experiments. The mice
were maintained according to the regulations set forth by the
Danish Laboratory Animal Ethical Committee. For all tumour
experiments, the cells for implantation were harvested from
subconfluent (70–80%) monolayer cultures by scraping with a
rubber policeman. The cell suspension (10 ´ 106 cells ml–1 in PBS)
was inoculated (2 ´ 106 cells per site) subcutaneously and bilater-
ally into the abdominal flanks of the recipient mice. The growth of
tumours was monitored by measurement every 2–3 days of
perpendicular diameters. Tumour volumes were estimated by
calculation using the formula 0.5 (width2 ´ length).
Blood was collected from anaesthetized mice by cardiac punc-
ture and rapidly mixed with cold trisodium citrate (0.1 vol) to give
a final concentration of 12.9 mM citrate. The plasma was separated
from blood cells within 1 h by centrifugation at 2000 g for
30 min at 4°C, and the supernatant was stored frozen at –80°C
prior to assay.
Xenograft tumours were surgically removed, cut into pieces and
immediately frozen in liquid nitrogen and stored at –80°C until
use. Frozen tumours were pulverized with a precooled powder
pistol. Tumour powder was suspended (100 mg tumour powder to
1 ml of lysis buffer) in lysis buffer (0.1 M Tris–HCl, pH 8.1, 1%
Triton X-114, 10 mM EDTA, 10 mg ml–1 aprotinin, 1 mM PMSF).
The extracts were assayed by ELISA for uPAR antigen level. In
addition, the extracts were subjected to temperature-induced phase
separation (Behrendt et al, 1990), and the resulting supernatants
were subsequently analysed by Western blotting (see below).
Protein concentration of the supernatants was determined using the
Bio-Rad protein assay (Bio-Rad, Richmond, CA, USA) with BSA
(Fraction V, Sigma) as standard.
Northern blotting
Total RNA was isolated from primary tumours established in the
nude mice from the two breast cancer cell lines, using the acid
guanidine–thiocyanate–phenol–chloroform method (Chomczynski
and Sacchi, 1987). The total amount of RNA isolated was deter-
mined from the absorption at OD260, assuming that 1 OD260 unit
is equivalent to 40  mg RNA.
The following DNA probes were used: p-uPAR-1, a plasmid
carrying the entire human uPAR cDNA (Roldan et al, 1990);
pHFbA-3¢UT, coding for the 3¢-untranslated region of human
b-actin cDNA (Ponte et al, 1984). The probes were labelled by the
random primer method (Feinberg and Vogelstein, 1983), using
dCTP 5¢-[a-32P]triphosphate.
For Northern blots 15 mg of total RNA from each sample were
size-fractionated by electrophoresis in 1.0% denaturating agarose
gels containing formamide and transferred to reinforced nitrocellu-
lose membranes (Rømer et al, 1994). Hybridization of blots was
carried out at 42°C for 16 h in 50% formamide, 10 ´ Denhardt’s
solution, 0.5% sodium dodecyl sulphate (SDS), 5 ´ sodium–saline
citrate (SSC), 200 mg ml–1 salmon sperm DNA, 10% dextran
sulphate, 200 mg ml–1 yeast–tRNA and 2 ´ 109 dpm  mg–1 of
32P-labelled probes. The filters were washed at 65°C for 1 h in
2 ´ SSC, 0.1% SDS and at 65°C for 1 h in 0.2 ´ SSC, 0.5% SDS
and at 65°C for 30 min in 0.1 ´ SSC, 0.5% SDS. Autoradiography
was performed at –80°C using Kodak T-MAT-G films and Kodak
Lanex X-Omatic intensifying screens.
Immunoabsorption and Western blotting
Mouse citrate plasma was diluted 1:10 in sample dilution buffer
(see ELISA above) to a final volume of 2 ml. The diluted sample
was recycled five times through a 2.0 ml column of protein
A-Sepharose (Pharmacia Biotech) in order to remove mouse IgG.
The run-through was then applied to and recycled five times
through a 1.0 ml column of protein A-Sepharose bearing the R2
monoclonal antibody to human uPAR, followed by extensive
washing. After plugging of the column, 200 ml of Laemmli Sample
BufferTM (Bio-Rad) was applied and the bound proteins were
eluted and heated to 90°C for 5 min. SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) of 50 ml of the resulting eluate
was run using a 12% acrylamide Ready GelTM (Bio-Rad), and the
proteins transferred electrophoretically from the gel onto a
polyvinylidene diflouride (PVDF) membrane (Millipore). The
membrane was blocked for 1 h at room temperature with 1%
skimmed milk powder in Tris-buffered saline (TBS), and after
washing, the membrane was incubated for 1 h at room temperature
with 20 ml of rabbit anti-human uPAR at a concentration of
5 mg ml–1. After washing again, treatment continued for 1 h at
23°C with 20 ml of a 1:1000 dilution of murine monoclonal
antibody to rabbit immunoglobulins conjugated with alkaline
phosphatase. Finally the membrane was washed extensively and
phosphatase substrate solution (NBT/BCIP, Sigma) was added to
develop colour.
For Western blotting of 48 h conditioned culture medium from
MDA-MB-231 BAG cells, the protein-A pre-absorption column
was omitted, and 20 ml of the medium was applied directly to the
R2 column or the anti-TNP column.
For tumour cell lysates and tumour tissue extracts, 25 ml of the
lysate was diluted 1:2 with Laemmli buffer and applied directly to
the running gel.
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Validation of shuPAR ELISA
The shuPAR ELISA method employed was capable of accurately
measuring recombinant shuPAR over a range of 3 pg ml–1 to more
than 1 ng ml–1. When this standard was added into a 1:10 dilution
of mouse citrate plasma the subsequent recovery of signal was
better than 90% (Figure 1). The sensitivity to recombinant shuPAR
was more than 1000-fold higher than towards recombinant mouse
suPAR (Figure 1).
Specificity of the ELISA was rigorously controlled by
immunoabsorption experiments as described (Stephens et al,
1997). When conditioned medium (48 h) from MDA-MB-231
BAG cells was absorbed on a protein A-Sepharose column using
an anti-uPAR monoclonal antibody (R4) against human uPAR
domain 3, different to the R2 antibody used in the ELISA, the
shuPAR signal in subsequent ELISA was reduced by approxi-
mately 95%.
Using the shuPAR ELISA, no signal above background was
obtained from the plasma of nude mice, unless they were host to
xenografted human tumours. After 8 weeks growth of subcuta-
neously implanted MDA-MB-231 BAG tumours, citrate plasma
from the host mice gave a substantial shuPAR signal (see below).
When this plasma pool was absorbed on a protein A-Sepharose
column using the mAb (R4), the signal in subsequent suPAR
ELISA was reduced by more than 95%. Thus xenografted human
tumours released detectable amounts of shuPAR into the plasma of
host mice.
Measurements of shuPAR released from breast tumour
cell lines
shuPAR was measured by ELISA in conditioned serum-free
media (SFM) from MDA-MB-231 BAG and MDA-MB-435 BAG
cells after 24 h of incubation. The concentration of shuPAR in
SFM from MDA-MB-231 BAG cells was 0.095 ±0.013 ng ml–1
corresponding to 2.2 ±0.14 fg ml–1 produced per cell per 24 h
(calculated on the basis of the cell number at 24 h). In MDA-MB-
435 BAG cultures, the concentration of shuPAR in 48 h condi-
tioned medium was below the detection limit of the ELISA.
To test the relationship between cell number and the shuPAR
released into culture supernatant, different numbers of MDA-MB-
231 BAG cells were grown in SFM for 48 h, so that there were
104 to 3 ´ 105 viable cells per well at the end of the experiment as
determined by MTT assay. When shuPAR was measured by
ELISA in the conditioned media, it was found that over the range
of cell density used there was a close correlation between cell
number and shuPAR concentration reached (linear correlation
coefficient  r > 0.99, P < 0.001, Figure 2A).
To establish whether shuPAR was continuously released by cells
into culture medium as a function of time, conditioned SFM from
MDA-MB-231 BAG cells was collected at different time points
between 2 and 48 h. For each time point the viable cell number was
estimated by the MTT method, and shuPAR levels were determined
by ELISA and normalized to 5 ´ 104 cells per well. Over this time
206 C Holst-Hansen et al
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Figure 1 Recovery of ELISA signal from recombinant human suPAR added
in increasing concentrations to assay dilution buffer (l), or a 1:10 dilution of
a mouse citrate plasma pool (l l). Recovery is also shown for ELISA signal
from recombinant mouse suPAR added in increasing concentrations to either
assay dilution buffer (n), or to a 1:10 dilution of a mouse citrate plasma pool
(n n). Values shown are the means of triplicates. The linear correlation
coefficient for each fitted line was >0.99
1.0
0.8
0.6
0.4
0.2
0.0
0 1 x 10
5 2 x 105 3 x 105
Cell number (at 48 h)
s
h
u
P
A
R
 
i
n
 
m
e
d
i
u
m
 
(
n
g
 
m
l
–
1
)
A
01 02 0 3 04 05 06 0
Incubation time (h)
s
h
u
P
A
R
 
i
n
 
m
e
d
i
u
m
 
(
n
g
 
m
l
–
1
 
p
e
r
 
5
 
x
 
1
0
4
 
c
e
l
l
s
)
0.25
0.20
0.15
0.10
0.05
0.00
B
Figure 2 (A) Release of shuPAR from MDA-MB-231 BAG breast cancer
cells in vitro. Selected numbers of MDA-MB-231 BAG cells were cultured for
48 h with 1 ml of serum-free medium (SFM). Aliquots of culture supernatants
were used for the ELISA of shuPAR. At the end of the experiment the cell
number was determined by the MTT-method. Results are expressed as the
mean ± s.d. of three independent shuPAR determinations. The linear
correlation coefficient for the fitted line was >0.99. (B) Release of shuPAR
from MDA-MB-231 BAG breast cancer cells in vitro. MDA-MB-231 BAG cells
(2.5 ´ 104 cells per well) were cultured for various periods of time with 1 ml of
SFM. Aliquots of culture supernatants were tested with the ELISA for
shuPAR. At the end of the experiment the cell number was determined by the
MTT-method, and the content of shuPAR in the culture supernatants was
normalized to 5 ´ 104 cells. Results are expressed as the mean ± s.d. of
three independent determinations. The linear correlation coefficient for the
fitted line was >0.99course the shuPAR level correlated closely with time (linear corre-
lation coefficient r > 0.99, P < 0.001, Figure 2B).
Characterization of uPAR in cell lysates and
conditioned medium
Cell lysates were made of cultured MDA-MB-231 BAG cells
using a Triton X-114 containing buffer together with the protease
inhibitors aprotinin, PMSF and EDTA, and then subjected to
temperature-induced phase separation (Solberg et al, 1994).
Western blotting of the total lysate, detergent phase and water
phase of Triton X-114 extracts (without immunoabsorption)
showed in all cases two bands corresponding to full-length uPAR
and a form consisting of uPAR domains (2+3) (Figure 3), i.e. a
cleavage product. No band corresponding to free domain 1 was
found in the Western blots of any of these fractions.
Using ultracentrifugation, we then tested whether shuPAR was
actually released in soluble form from the cells into the medium,
or if vesiculation or blebbing of sedimentable microparticles
occurred from the plasma membrane. Medium conditioned by
MDA-MB-231 BAG cells for 24 h was either centrifuged at
10 000 g for 5 min at 4°C or centrifuged at 105 000 g for
60 min at 4°C, and the concentration of shuPAR determined by
ELISA in the resulting supernatants. There was no significant
reduction in the concentration of shuPAR measured in the super-
natants after either centrifugation (data not shown), suggesting that
shuPAR was not present in vesicles or bound to membrane parti-
cles. This is in contrast to the findings on sedimentable membrane
particles reported to occur in culture supernatants from HT1080
cells (Ginestra et al, 1997).
In order to characterize the molecular form(s) of shuPAR
measured in conditioned medium, the R2 monoclonal antibody to
human uPAR domain 3 was used for immunoabsorption, and
Western blotting was performed on the absorbed shuPAR. In
contrast to the mixture of cleaved and uncleaved uPAR found in
cell lysates (see above), only full-length three-domain shuPAR
was found in the medium from MDA-MB-231 BAG cells
(Figure 4). Immunoabsorption and Western blotting was not
performed on conditioned medium or cell lysates from MDA-
MB-435 BAG cells due to the low shuPAR content.
Characterization of uPAR in extracts of human tumour
xenografts
MDA-MB-231 BAG and MDA-MB-435 BAG tumours grown in
nude mice were extracted and analysed by Northern and Western
blotting, as well as by ELISA for human uPAR. Northern blot
shuPAR in plasma from tumour xenografted nude mice 207
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Figure 3 Western blot analysis of cell extracts of MDA-MB-231 BAG cells.
Twenty-five microlitres of total lysate (lane 3), detergent phase (lane 4) and
water phase (lane 5) of Triton X-114 extracts (see text) of MDA-MB-231 BAG
cells were analysed by Western blotting using polyclonal rabbit anti-human
uPAR antibody. The standards consisted of purified full-length shuPAR (lane
1, ~ 100 pg), and chymotrypsin cleaved shuPAR domains (2+3), (lane 2,
~ 200 pg). The arrows indicate the position of full-length shuPAR and
shuPAR domains (2+3). Electrophoretic mobility of standard proteins is
indicated to the right
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Figure 4 Western blot analysis of culture supernatants of MDA-MB-231
BAG cells. Forty-eight hours conditioned medium was immunoabsorbed on
either an anti-uPAR-R2 column (lane 3) or an anti-TNP column (lane 4), and
then analysed together with standards of purified full-length shuPAR (lane 1,
~ 100 pg), and chymotrypsin-cleaved shuPAR domains (2+3), (lane 2,
~ 200 pg), by Western blotting using polyclonal rabbit anti-human uPAR
antibodies
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Figure 5 Northern blot analysis for human uPAR mRNA of extracts of
MDA-MB-231 BAG and MDA-MB-435 BAG tumour xenografts. Total RNA
was electrophoresed in agarose gels under denaturating conditions and
blotted onto a nitrocellulose membrane. The membrane was hybridized with
a human cDNA probe for uPAR. Lane 1 contained RNA from MDA-MB-435
BAG tumours and lane 2 contained RNA from MDA-MB-231 BAG tumours.
The lanes were loaded with 15 mg of total RNA. The lower section shows a
control rehybridization of the membrane with a b-actin cDNA probe. The
electrophoretic mobility of ribosomal RNAs is indicated to the leftanalysis of the xenografted tumours showed that MDA-MB-231
BAG tumours had considerably higher uPAR mRNA expression
than MDA-MB-435 BAG tumours (Figure 5) and correspond-
ingly, approximately 5- to 6-fold higher uPAR protein levels
(1.074 ± 0.339 ng mg–1 protein) than MDA-MB-435 BAG
tumours (0.185 ± 0.024 ng mg–1 protein). Western blot analysis of
MDA-MB-231 BAG tumour tissue total extracts and detergent
phase extracts showed two bands, the upper band corresponding to
full-length uPAR and the lower band corresponding to uPAR
domains (2+3), but only one band (full-length uPAR) was found in
the water phase of Triton X-114 extracts. Note that the extraction
buffer used included the protease inhibitors aprotinin, PMSF and
EDTA (Figure 6). The mobility of the uPAR bands from the
tumour extracts did not exactly correspond to the mobility of
standard uPAR, probably due to differences in glycosylation
(Rønne et al, 1994). A similar Western blot was performed using
extracts of MDA-MB-435 BAG tumours, which also showed both
full-length uPAR and uPAR domains (2+3) in the total extracts
(data not shown). However in these Western blots apparently
neither of the two tumour extracts contained free domain 1, as
would have been expected from the proteolytic cleavage of uPAR.
Measurements of shuPAR in plasma from mice with
human tumours: relationship between tumour burden
and plasma shuPAR
Mice carrying either MDA-MB-231 BAG or MDA-MB-435 BAG
tumours had significant levels of shuPAR in their plasma. At a
mean tumour volume of 1 cm3, mice carrying MDA-MB-231
BAG tumours had 0.20 ng shuPAR ml–1 while mice carrying a
1c m 3 MDA-MB-435 BAG tumour had 3.4 ng shuPAR ml–1 in
plasma. To study the relationship between released shuPAR and
tumour burden, 97 mice were inoculated subcutaneously and
bilaterally with MDA-MB-231 BAG tumour cells. Tumours were
allowed to grow for 6 weeks (n = 24 mice) or 8 weeks (n = 73
mice). At these two time points tumour volume was measured and
blood was taken for citrate plasma by cardiac puncture. The
combined tumour volume for the tumours on the left and right
flanks differed for the individual mice in each group, representing
the following intervals: 670 mm3 to 7340 mm3 (6 weeks of tumour
growth) and 1340 mm3 to 22 200 mm3 (8 weeks of tumour
growth). The plasma samples from individual mice were measured
by ELISA for shuPAR content. The mean level of plasma shuPAR
in the two groups was as follows: 0.54 ± 0.41 ng ml–1 (6 weeks of
tumour growth); 1.23 ± 1.3 ng ml–1 (8 weeks of tumour growth).
When the shuPAR levels were plotted against the corresponding
total tumour volume for each individual mouse, it was found
that plasma shuPAR correlated significantly with tumour volume
(linear correlation coefficient r = 0.74, P < 0.0001, Figure 7A).
In order to test whether the correlation between plasma shuPAR
and tumour volume could be observed for another type of cancer
xenograft, the human colon tumour cell line, HCT 116, was inocu-
lated subcutaneously and bilaterally into 16 nu/nu–META/Bom
mice. Tumours were allowed to grow for 5 weeks (n = 9 mice) or
8 weeks (n = 7 mice). The combined tumour volume for the
tumours on the left and right flanks differed for the individual mice
in each group, representing the following intervals: 1340 mm3 to
4470 mm3 (5 weeks of tumour growth) and 600 mm3 to 5260 mm3
(8 weeks of tumour growth). The mean tumour volume between
the two groups was not significantly different. The plasma samples
from individual mice were measured by ELISA for shuPAR
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Figure 6 Western blot analysis of extracts of MDA-MB-231 BAG tumour
xenografts. Twenty-five microlitres of total lysate (lane 3), detergent phase
(lane 4) or water phase (lane 5) of Triton X-114 extracts (see text) of MDA-
MB-231 BAG tumours were analysed by Western blotting using polyclonal
rabbit anti-human uPAR antibodies. The standards consisted of purified full-
length shuPAR (lane 1, ~ 100 pg), and chymotrypsin-cleaved shuPAR
domains (2+3), (lane 2, ~ 200 pg)
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Figure 7 Comparison between tumour volume and plasma shuPAR level.
(A) The content of shuPAR in individual host plasma samples from mice
xenografted with MDA-MB-231 BAG tumour cells was plotted against the
total tumour volume of the tumours on the left and the right flanks of each
mouse. The linear correlation coefficient was r = 0.74, P < 0.0001. (B) The
content of shuPAR in individual host plasma samples from mice xenografted
with HCT 116 tumour cells was plotted against the total tumour volume of the
tumours on the left and the right flanks of each mouse. The linear correlation
coefficient was r = 0.81, P < 0.0001content. The mean level of plasma shuPAR in the two groups
was as follows: 0.73 ± 0.55 ng ml–1 (5 weeks of tumour growth);
0.66 ± 0.44 ng ml–1 (8 weeks of tumour growth). When the plasma
shuPAR levels were plotted against the corresponding total tumour
volume for each individual mouse, it was found that plasma
shuPAR correlated closely with tumour volume (linear correlation
coefficient r = 0.81, P < 0.0001, Figure 7B). The amount of uPAR
protein in HCT 116 tumour extracts was 0.728 ± 0.123 ng mg–1
protein, and Western blot analysis of the tumour tissue extracts
showed two bands, the upper band corresponding to full-length
uPAR and the lower band corresponding to uPAR domains (2+3)
(data not shown).
Characterization of shuPAR in plasma from mice with
human tumours
To characterize the molecular form(s) of shuPAR measured in
the plasma of mice bearing human tumour xenografts, plasma was
immunoabsorbed with the R2 monoclonal antibody to uPAR, and the
immunoconcentrated shuPAR was then examined by Western blot-
ting. Plasma from mice with MDA-MB-231 BAG tumours showed
only one band corresponding to full-length shuPAR, and no shuPAR
was found in the form of domains (2+3) (Figure 8). A similar
Western blot was performed using plasma from mice with MDA-
MB-435 BAG and HCT 116 tumours, which also showed only one
band corresponding to full-length shuPAR (data not shown).
DISCUSSION
This study was facilitated by the use of a newly developed shuPAR
ELISA which achieves a high level of sensitivity while main-
taining strict specificity for human uPAR. The assay was tested in
several different ways in both purified systems as well as with
internal controls of recombinant shuPAR and smuPAR added into
a pool of mouse plasma. Specificity was also rigorously controlled
by immunoabsorption experiments. Since the assay was over 1000
times more sensitive to huPAR than muPAR, and signal was only
found at significant levels in plasma from mice bearing human
tumours, it was concluded that the suPAR signal measured in
plasma from tumour-bearing mice represented shuPAR.
By applying the shuPAR ELISA to conditioned media from
MDA-MB-231 BAG human breast cancer cells, it was confirmed
that these cells released shuPAR into the medium. The release of
shuPAR was both time-and cell number-dependent, suggesting a
constant and direct correlation between cell number and amount
of shuPAR released from the cells. Furthermore, when the two
human breast cancer cell lines were grown as solid tumours in
nude mice, shuPAR was released from the tumour cells into the
blood. A highly significant correlation was found between tumour
volume and plasma shuPAR concentration in MDA-MB-231 BAG
and HCT 116 xenografted mice, indicating that plasma levels of
shuPAR reflect tumour burden in the host mice.
The close correlation between plasma shuPAR content and
tumour volume suggests that shuPAR may be useful in monitoring
increasing or decreasing tumour burden. We have recently found
that patients with metastatic breast, lung and colon cancer have
increased levels of shuPAR in their blood (Pappot et al, 1997;
Stephens et al, 1997), and that plasma suPAR levels correlate with
stage of disease and patient survival in colorectal and ovarian
cancer patients (Stephens et al, 1997; Sier et al, 1998). It remains
to be demonstrated, however, both in the experimental mouse
model and in cancer patients, whether plasma levels of shuPAR
also will reflect tumour regression, when growth is impaired by an
anti-tumour agent such as a cytotoxic drug, i.e. whether shuPAR
can be used as a surrogate end point in the treatment of cancer
patients.
The mAb R2 used in the ELISA is directed against an epitope
located in domain 3 of uPAR. Thus, the assay will detect both
full-length uPAR and the form consisting of domains (2+3). In
order to further characterize the form(s) of shuPAR measured
in cell culture supernatants, Western blot experiments were
performed. It was found that in conditioned medium of MDA-MB-
231 BAG cells, only the full-length form of shuPAR was released
from the tumour cells and not the domains (2+3) form seen in cell
lysates. This suggests that either a phospholipase cleavage of the
GPI-anchor or a proteolytic cleavage at the carboxy-terminal end
of uPAR could have taken place. Since shuPAR was released under
serum-free conditions, it seems that the underlying mechanism(s)
involves cell-associated processes.
The study was then extended to investigate the form(s) of
shuPAR measured in plasma from the mice bearing the human
tumours. The MDA-MB-231 BAG human cancer cells were
injected into nude mice and allowed to form solid tumours.
Western blotting of immunoconcentrated plasma from mice with
MDA-MB-231 BAG tumours showed the presence of full-length
shuPAR in vivo, which is in agreement with the findings in condi-
tioned medium and in patients with different forms of cancer
(Stephens et al, manuscript in preparation). Similar results were
obtained in plasma from both MDA-MB-435 BAG and HCT 116
tumour-bearing animals. Thus, despite the presence of domains
(2+3) in cell and tumour extracts, only the full-length receptor was
detected in conditioned media and plasma. However, due to the
detection limit of the Western blotting, it cannot be completely
excluded that a minor fraction of domains (2+3) and domain
1 uPAR is present in conditioned medium and/or plasma. One
possible explanation for this differential release could be that
domains (2+3) uPAR is somehow protected against further
enzymatic cleavage which would release it from the cell surface.
In human breast and colon carcinomas, uPAR is expressed by
tumour-infiltrating macrophages in addition to the cancer cells
(Pyke et al, 1991, 1993). In our breast and colon cancer xenograft
shuPAR in plasma from tumour xenografted nude mice 209
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Figure 8 Western blot analysis of citrate plasma from mice xenografted
with MDA-MB-231 BAG tumours. A pool of citrate plasma from mice with
MDA-MB-231 BAG tumours was immunoabsorbed on either an anti-uPAR-
R2 column (lane 3) or an anti-TNP column (lane 4), and then analysed
together with purified full-length shuPAR (lane 1, ~ 100 pg), and cleaved
shuPAR domains (2+3), (lane 2, ~ 200 pg), by Western blotting using
polyclonal rabbit anti-human uPAR antibodiesmodels, the measured suPAR is clearly derived from the human
cancer cells, so this may only partially represent the situation for
release of suPAR in cancer patients. However, our models may be
useful in studying the mechanism by which suPAR is released
from tumour cells in vivo.
One possible biological role of shuPAR could be as a scavenger
for uPA, thus reducing the proportion of uPA bound to cell-surface
uPAR (Masucci et al, 1991). It has been shown in vitro that
relatively high concentrations of suPAR can act as a scavenger for
uPA and thereby inhibit uPA mediated proliferation and Matrigel
invasion of human tumour cells (Wilhelm et al, 1994). However,
this role is not thermodynamically favoured in vivo, since the
physiological concentrations of both uPA and uPAR in plasma
(approximately 20 pM) are well below that required for a signifi-
cant level of interaction (Kd = 0.1 nM). At the pericellular level,
however, local shuPAR levels may reach levels that could atten-
uate uPA dependent tumour cell behaviour. Another putative role
of suPAR could be as a chemotactic stimulator, although this
activity is specifically related to the chymotrypsin-cleaved suPAR,
i.e. domains (2+3) uPAR (Resnati et al, 1996). In addition, suPAR
could contribute to enhanced detachment of tumour cells from the
surrounding extracellular matrix by competing with cell-surface
uPAR for vitronectin binding (Høyer-Hansen et al, 1997; Chavakis
et al, 1998).
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